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Abstract: Colorectal cancer (CRC) is one of the most common malignancies worldwide. Inflammation
contributes to cancer development and inflammatory bowel disease is an important risk factor for
CRC. The aim of this study is to assess whether a widely used probiotic Enterococcus faecalis can
modulate the NLRP3 inflammasome and protect against colitis and colitis-associated CRC. We studied
the effect of heat-killed cells of E. faecalis on NLRP3 inflammasome activation in THP-1-derived
macrophages. Pretreatment of E. faecalis or NLRP3 siRNA can inhibit NLRP3 inflammasome activation
in macrophages in response to fecal content or commensal microbes, P. mirabilis or E. coli, according to
the reduction of caspase-1 activation and IL-1β maturation. Mechanistically, E. faecalis attenuates the
phagocytosis that is required for the full activation of the NLRP3 inflammasome. In in vivo mouse
experiments, E. faecalis can ameliorate the severity of intestinal inflammation and thereby protect
mice from dextran sodium sulfate (DSS)-induced colitis and the formation of CRC in wild type mice.
On the other hand, E. faecalis cannot prevent DSS-induced colitis in NLRP3 knockout mice. Our
findings indicate that application of the inactivated probiotic, E. faecalis, may be a useful and safe
strategy for attenuation of NLRP3-mediated colitis and inflammation-associated colon carcinogenesis.
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1. Introduction
Colorectal cancer (CRC) is one of the most common malignancies worldwide, with an estimated
135,430 new cases predicted for 2017 in the United States [1]. It is commonly accepted that inflammation
contributes to cancer development, and inflammatory bowel disease (IBD) is known to be an important
risk factor for CRC development [2]. IBD represents a group of intestinal disorders caused by
inflammation of the gastrointestinal tract [3]. The two major types of IBD are ulcerative colitis and
Crohn’s disease. Ulcerative colitis causes inflammation in the mucosa of the colon and rectum, while
Crohn’s disease affects all parts of the gastrointestinal tract, from the mouth to the anus. Both diseases
are characterized by a series of relapses and remissions. The etiology and pathogenesis of IBD remain
largely unclear. Several lines of evidence suggest that dysbiosis in enteric microbiota and defective
innate immunity are two key players [4].
Enterococcus faecalis is a Gram-positive and facultative anaerobic commensal bacterium that
belongs to the group of lactic acid bacteria. For a long time now, E. faecalis has been widely used as
a probiotic product [5]. The World Health Organization defines probiotics as “live microorganisms,
which when adminutesistered in adequate amounts, confer a health benefit on the host”. However,
mounting evidence indicates that dead lactic acid bacteria, including E. faecalis, may also exert
immunomodulatory effects [6,7]. Studies have indicated that dead probiotics are safer than live
probiotics due to the decreased risk for systematic infection and/or transfer of antibiotic genes [8].
Therefore, dead probiotics could be particularly beneficial in children and immunocompromised
people [6,7]. The results of numerous clinical trials indicate that heat-killed probiotic bacteria can have
health benefits, such as by reducing skin disease in adult atopic dermatitis patients [9], improving
the life quality for patients with allergic rhinitis [10], decreasing the incidence of upper respiratory
tract infection in healthy people with psychological stress [11], and enhancing immunity in elderly
people [12]. Previous studies found that oral adminutesistration of lysed E. faecalis can reduce
the allergen-induced immune response in mice [13] and that heat-killed E. faecalis can modulate
monocyte chemoattractant protein-1 and reduce the pathogenicity of influenza and enterovirus 71
infections [7]. Notably, pretreatment with viable or heat-killed E. faecalis has been shown to have
protective effects against colitis in dextran sodium sulfate (DSS)-induced colitis in mice and small
intestinal cancer formation in Apc mutant Minutes mice [14,15]. However, the effect of E. faecalis
pretreatment on colitis-associated CRC and the potential mechanisms underlying this protective effect
remains largely unknown.
NLRP3 inflammasomes are cytoplasmic multiprotein complexes that are important for innate
immunity. They consist of the cytosolic pattern recognition receptor, NLRP3, the adaptor protein,
ASC, and pro-caspase-1 [16]. The assembly of the NLRP3 inflammasome is responsible for activating
pro-caspase 1 p45 to produce cleaved caspase-1 p10, which subsequently mediates the maturation
of the pro-inflammatory cytokines, pro-IL-1β p31 and pro-IL-18 p24, to generate the secondsretable
forms, IL-1β p17 and IL-18 p18. A two-signal model has been proposed to explain the regulation
of the NLRP3 inflammasome [17]: the first signal (priminutesg) enables the expression of NLRP3,
pro-IL-1β and pro-IL-18; and the secondsond signal (activation) is triggered by pathogen-associated
molecule patterns (PAMPs) and damage-associated molecular patterns (DAMPs; e.g., nigericin [18]
and ATP [19]) and leads to the assembly of the NLRP3 inflammasome. In colon tissues, NLRP3 and
IL-1β are expressed in both healthy and colitic states [20]. The function of the NLRP3 inflammasome
is important for healthy states, as seen in its contribution to the recovery of intestinal tissue damage
in DSS-treated colitic mice [21]. However, excessive activation of the NLRP3 inflammasome results
in development of several inflammatory diseases, including septic shock [22], type 2 diabetes [23],
cryopyrin-associated periodic syndromes [24], rheumatoid arthritis [25], and Alzheimer’s disease [26].
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Recently, Seo et al. provided evidence that activation of the NLRP3 inflammasome is also involved
in promoting colitis in the DSS-treated mouse model [27]. Finally, studies have shown that certain
members of the microbiota, especially Proteus mirabilis, can induce robust IL-1β production via the
NLRP3 inflammasome in recruited inflammatory macrophages, and thereby promote IL-1β-dependent
inflammation and damage in the intestine [27].
Here, we demonstrate that pretreatment with heat-killed E. faecalis can inhibit the induction of
IL-1β secondsretion in macrophages stimulated with fecal content and two commensal microbes,
P. mirabilis and E. coli. Mechanistically, E. faecalis attenuates the phagocytosis that is required for full
activation of the NLRP3 inflammasome. Finally, we show that E. faecalis can ameliorate the severity of
intestinal inflammation and protect mice from DSS-induced colitis and the formation of CRC.
2. Materials and Methods
2.1. Reagents and Antibodies
PMA (cat# P1585), ATP (cat# A7699), nigericin (cat# N7143), 4′,6-diamidino-2-phenylindole
(DAPI; cat# D9542), and cytochalasin D (cat# C8273) were purchased from Sigma-Aldrich (St Louis,
MO, USA), anti-ASC (cat# SC-22514-R), anti-human caspase-1 (cat# SC-56036), anti-mouse caspase-1
(cat# SC-514), anti-human IL-1β (cat# SC-32294), anti-α-tubulin (cat# SC-32293), anti-GAPDH (cat#
SC-32233), and goat anti-rabbit IgG-horseradish peroxidase (HRP; cat# SC-2004) from Santa Cruz
Biotechnology (Santa Cruz, CA, USA); anti-NLRP3 (cat# AG-20B-0014) from Adipogen (San Diego, CA,
USA), anti-mouse IL-1β (cat# AF-401-NA) from R&D Systems Inc. (Minutesneapolis, MN, USA); sheep
anti-mouse IgG-HRP (cat# NA931) from Amersham (Amersham, UK), (5-(and-6)-carboxyfluorescein
diacetate, succinimidyl ester (CFSE; cat# C1157) and Alexa Fluor-594 conjugated goat-anti-mouse IgG
(H+L) (cat# A-11005) from Invitrogen (Carlsbad, CA, USA); and fluoresbrite yellow green carboxylate
microspheres (1-µm YG beads, cat# 15702) from Polysciences Inc. (Warrington, PA, USA).
2.2. Preparation of Probiotic, Bacteria, and Fecal Content
The probiotic E. faecalis strain KH2 (Cosmo Foods, Tokyo, Japan) was originally isolated from a
fruit. E. faecalis cells were killed by heat treatment at 80 ◦C for 30 min. The heat-killed E. faecalis were
lyophilized and stored at −80 ◦C until use. E. coli (DH5α) was obtained from Real Biotech Corporation.
P. mirabilis (ATCC 12453) was obtained from the American Type Culture Collection. For preparation
of fecal content, fresh fecal pellets were collected from C57BL/6 mice, 100 mg/mL were vortexed in
PBS for 30 min, and the fecal homogenate was collected by centrifugation at 1000 rpm for 5 s. For
heat inactivation, the fecal content was heat treated at 100 ◦C for 5 min. For UV inactivation, the fecal
content was exposed to UV for 30 min. The number of CFU per milliliter of bacterial suspension was
calculated using a DensiCHEK instrument (bioMerieux Inc., Hazelwood, MO, USA).
2.3. Cell Culture
The human leukemia monocytic THP-1 cell line was maintained in RPMI and stimulated
to macrophages with 200 nM PMA for 16 h as described previously [28]. For measurement of
inflammasome activation, the THP-1 cells were treated with fecal content (1:200 dilution of stock),
E. coli (MOI 100) or P. mirabilis (MOI 100) for 3 h, with 10 µM nigericin for 1 h, or with 5 mM ATP for
4 h. To examinutese the effects of E. faecalis on cells stimulated with fecal content, E. coli or P. mirabilis,
PMA-differentiated THP-1 cells were pretreated with 1, 2, or 4 mg/mL of E. faecalis as indicated. At
24 h after E. faecalis incubation, THP-1 cells were stimulated with fecal content, heat-inactivated fecal
content, UV-irradiated fecal content, E. coli, or P. mirabilis for 3 h.
2.4. RNA Interference
Transfection of the dsRNA duplexes (50 nM) was performed using Lipofectaminutese 2000
(Invitrogen) as previously described [29]. The cells were harvested and analyzed at two days
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post-transecondstion. The reagent used to target NLRP3 (cat# HSS132811-3, Invitrogen) included three
25-bp RNA duplexes: 5′-AAAGG AAGAA GACGU ACACC GCGGU-3′, 5′-ACCGC GGUGU ACGUC
UUCUU CCUUU-3′ and 5′-UUAGC UUUGG CUUUC ACUUC AAUCC-3′.
2.5. Immunoblot Analysis
Immunoblot analysis has been described previously [28]. Briefly, cells were lysed in RIPA buffer
containing a protease inhibitor cocktail on ice for 30 min. For measurement of IL-1β secondsretion
and caspase-1 activation, culture supernatants were collected and concentrated by trichloroacetic acid
(TCA; cat# T9159) precipitation. The protein lysates (from culture cells) or precipitated protein samples
(from culture supernatants) were resolved by SDS-PAGE and transferred to nitrocellulose membranes
(Amersham). The membranes were incubated with the indicated primary antibodies (1:1000 dilutions
of indicated antibody except anti-GAPDH antibody, which was at 1:2000), and then with an
HRP-conjugated secondsondary antibody (1:5000 dilutions of each antibody). The immunoreactive
bands were detected using the TOOLS Extreme ECL-HRP Substrate (cat# TU-ECL03; Biotools, Taiwan).
2.6. CFSE Labeling of Bacteria and Fecal Content
Bacteria and fecal content were washed twice with PBS, suspended in PBS containing 10 µM
CFSE, and incubated in for 30 min under gentle agitation at 37 ◦C. CFSE-labeled bacteria and fecal
content were washed three times with PBS prior to use.
2.7. Phagocytosis Assay
PMA-differentiated THP-1 cells were preincubated with 2 mg/mL of E. faecalis for 24 h or with
10 µM cytochalasin D for 1 h, followed stimulation with YG beads (10 beads/cell), fecal content, E. coli
(MOI 100) or P. mirabilis (MOI 100) for 3 h. Cells were stained for visualization of tubulin (1:100 dilution
of anti-α-tubulin followed by a 1:1000 dilution of Alexa Fluor-594 conjugated secondsondary antibody
(Invitrogen, red), YG beads, fecal content, E. coli or P. mirabilis (CFSE, green) and nuclei (DAPI, blue).
To demonstrate the phagocytic efficiency of THP-1 cells, images were obtained with a confocal laser
scanning microscope (LSM780; Carl Zeiss, Jena, Germany) and processed with the ZEN microscopic
software (Carl Zeiss). The phagocytic activity was quantified by calculating the percentage of cells with
internalized YG beads, CFSE-labeled fecal content or bacteria, as assessed using an IN cell analyzer
(GE Healthcare, Freiburg, Germany).
2.8. ELISA
Cell culture supernatants were assayed for human IL-1β using a commercially available ELISA
kit (cat# 88-7261; eBioscience, San Diego, CA, USA).
2.9. Animal Experiments
Mouse experiments were approved by and performed according to the guidelines of the
Institutional Animal Care and User Committee of Chang-Gung University (CGU15-206). C57BL/6
mice were purchased from the National Laboratory Animal Center, Taiwan. Mice were maintained
under specific pathogen-free conditions. For the induction of colitis, 2.5% DSS (molecular weight,
36,000–50,000; MP Biomedicals, Aurora, OH, USA) was given to mice (6–9 weeks old) via the drinking
water as described previously [30]. To evaluate the effect of E. faecalis on DSS-induced colitis, mice
were orally inoculated with E. faecalis (17 mg/kg) every day during the course of experiment, starting
two weeks before the adminutesistration of DSS. For generation of colitis-associated CRC model, mice
were injected intraperitoneally with azoxymethane (AOM; 10 mg/kg; cat# A5486; Sigma-Aldrich)
prior to beginning the first of three or four cycles of DSS in drinking water as indicated. One cycle was
defined as 6 days of DSS followed by 14 days of water. To evaluate the effect of E. faecalis on the mouse
model of colitis-associated CRC, mice were orally inoculated with E. faecalis (17 mg/kg) every day
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during the course of experiment, starting two weeks before the adminutesistration of DSS or at the
end of the third DSS treatment. Body weight and diarrhea were recorded daily. Scoring for severity
of diarrhea was performed as described previously [31] with a slight modification. Briefly, diarrhea
scores were determinutesed as follows: 0 points for well-formed stools, 1 point for soft but formed
stools, 2 points for pasty and semiformed stools that did not adhere to the anus (mild diarrhea), 3
points for slimy stool (moderate diarrhea), 4 points for liquid stools that did adhere to the anus (severe
diarrhea). The colon length and number of tumors per colon were measured at the time of sacrifice.
2.10. Statistical Analysis
Data from in vitro experiments and tumor growth in the mouse model were analyzed with the
ANOVA test followed by Bonferroni post hoc test as indicated or Student’s t-test in SPSS as described
previously [30]. Differences were considered significant at p < 0.05.
3. Results
3.1. NLRP3 Inflammasome is Required for Commensal Bacteria-Induced IL-1β Secondsretion
To confirm that IL-1β secondsretion can be induced through commensal bacteria-mediated
NLRP3 inflammasome activation [27], we measured secondsreted IL-1β in cultures of THP-1-derived
macrophages treated with fecal content or commensal bacteria. We assessed the expression of active
caspase-1 p10 and mature IL-1β p17 by Western blot analysis, and examinutesed the level of IL-1β
by ELISA. As shown in Figure 1a, we observed increased amounts of active caspase-1, mature IL-1β
and secondsreted IL-1β in THP-1 cell cultures treated with fecal content, and found that these levels
were reduced in cells treated with NLRP3-specific small interfering RNA (siRNA) but not control
siRNA. Similarly, active caspase-1, mature IL-1β, and secondsreted IL-1β were induced by infection
with either E. coli or P. mirabilis, and this induction was reduced by NLRP3 knockdown (Figure 1b).
Our results show that fecal content and the tested commensal bacteria can induce IL-1β secondsretion
through the NLRP3 inflammasome in macrophages.
3.2. Probiotic E. faecalis Attenuates Bacteria-Induced IL-1β Secondsretion
It has been reported that inactivated E. faecalis may improve allergy symptoms and reduce the
pathogenicity of viral infection through immunomodulatory effects [7,13,32,33]. However, it was not
known whether or how E. faecalis could modulate the commensal bacteria-induced activation of the
NLRP3 inflammasome. We therefore evaluated the effect of E. faecalis pretreatment on inflammasome
activation by assessing caspase-1 activation and IL-1β maturation in THP-1 cells. Our results indicated
that the levels of active caspase-1 and mature IL-1β induced by either fecal content treatment (Figure 2a)
or infection with E. coli or P. mirabilis (Figure 2b) were decreased in THP-1 cells pretreated with E.
faecalis compared with untreated cells. Consistently, E. faecalis pretreatment also suppressed the IL-1β
secondsretion induced by fecal content treatment (Figure 2c) or infection with E. coli or P. mirabilis
(Figure 2d). The suppressive effect of E. faecalis on fecal content-induced IL-1β secondsretion appeared
to be dose-dependent (Figure 2c), and the effect against commensal bacteria was observed in THP-1
cells infected with different doses of E. coli or P. mirabilis (Figure 2d). Taken together, our results suggest
that E. faecalis pretreatment can efficiently attenuate fecal content- or commensal bacteria-induced
NLRP3 inflammasome activation and IL-1β secondsretion.
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casp-1 p10, active caspase-1 subunits; IL-1β p17, secondsreted mature IL-1β; procasp-1, p45 precursor
of caspase-1; and pro-IL-1β, p31 precursor of IL-1β.
3.3. Probiotic E. faecalis Attenuates Bacteria-Induced NLRP3 Inflammasome Activation by Decreasing
Bacterial Phagocytosis
Bacteria-induced NLRP3 inflammasome activation is thought to be regulated by at least two
pathways [34,35]: in the first, phagocytosis of extracellular bacteria results in lysosomal destabilization
and the release of cathepsin B; and in the secondsond, extracellular exposure to a bacterial
pore-forminutesg toxin or ATP results in potassium efflux and a decrease of intracellular potassium. To
explore which pathway is affected by E. faecalis treatment, we first examinutesed the effect of E. faecalis
on phagocytosis in our system. The efficiencies of non-specific or bacterial phagocytosis were evaluated
by monitoring the uptake of fluorescence-labeled polystyrene latex beads or bacteria, respectively. As
shown in Figure 3a, pretreatment of E. faecalis caused clearly intracellular, phagocytosed E. faecalis.
The uptake efficiency of fluorescent beads by THP-1 cells was significantly decreased when cells were
pretreated with E. faecalis (Figure 3a). The phagocytosed E. faecalis appear to exhaust the capacity
of phagocytosis in macrophages. Similarly, E. faecalis also significantly inhibited the phagocytosis
of fecal content, E. coli and P. mirabilis (Figure 3b and Figure S1). Next, we used the phagocytosis
inhibitor, cytochalasin D, to evaluate the role of phagocytosis in commensal bacteria-induced IL-1β
secondsretion in our system. As shown in Figure 3c, cytochalasin D reduced the phagocytosis of fecal
content and inhibited fecal content-induced IL-1β secondsretion (Figure 3d). Consistently, cytochalasin
D also reduced E. coli- and P. mirabilis-induced IL-1β secondsretion (Figure 3d). These results indicate
that bacterial phagocytosis is required for bacteria-induced NLRP3 inflammasome activation and IL-1β
secondsretion, and that E. faecalis can interfere with phagocytosis to attenuate the bacteria-induced
activation of the NLRP3 inflammasome.
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results are presented as the mean ± SD of three independent experiments. Abbreviations: casp-1 p10, 
i re 2. . faecalis attenuates bacteria-induced IL-1β secondsretion. (a, ) I l t a al sis f
L P3 infla asome molecules in cell SN and CL from THP-1-derived macrophages pretreated with
E. faecalis (2 mg/mL) for 24 h and then incubated for 3 h with (a) FC, (b) Ec (MOI 100) or Pm (MOI
100). The western blot is a representative of three independent experiments. (c,d) ELISA of IL-1β in the
SN of THP-1-derived macrophages pretreated with E. faecalis at the dose as indicated (c) or 2 mg/mL
(d) for 24 h and then infected for 3 h with FC (c), or Ec or Pm at 20, 50 or 100 MOI (d). ELISA data
were analyzed with the ANOVA test followed by post hoc test. *, p < 0.05; and **, p < 0.01. All results
are presented as the mean ± SD of three independent experiments. Abbreviations: casp-1 p10, active
caspase-1 subunits; IL-1β p17, secondsreted mature IL-1β; procasp-1, p45 precursor of caspase-1; and
pro-IL-1β, p31 precursor of IL-1β.
3.4. Probiotic E. faecalis Induces Pro-IL-1β Expression but Does Not Affect ATP- or Nigericin-Induced
NLRP3 Inflammasome Activation
Since bacteria can also activate the NLRP3 inflammasome through bacterial pore-forminutesg
toxin- or ATP-mediated potassium efflux [34,35], we examinutesed the potential effect of E. faecalis
on bacterial toxin- and ATP-induced NLRP3 inflammasome activation. As shown in Supplementary
Figure S2a, E. faecalis significantly increased the ATP- or nigericin (a pore forminutesg toxin)-induced
levels of mature IL-1β but did not affect the amount of active caspase-1. Consistent with increase of
mature IL-1β, E. faecalis induced the expression of pro-IL-1β, regardless of the presence of ATP or
nigericin (Supplementary Figure S2a). Furthermore, E. faecalis treatment increased IL-1β secondsretion
in a dose-dependent manner, regardless of the presence of ATP or nigericin (Supplementary Figure
S2b). Together, these results suggest that E. faecalis can contribute to ATP- and nigericin-induced
IL-1β secondsretion through the upregulation of pro-IL-1β expression rather than through NLRP3
inflammasome activation.
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by E. faecalis. (a,b) THP-1-derived macrophages were pretreated with E. faecalis (Ef, 2 mg/mL) for
24 h, incubated for 3 h with (a) beads, (b) FC, Ec or Pm, and assessed for phagocytosis. Scale bars,
20 µm. Phagocytosis was quantified with an IN Cell Analyzer. (c) Assessment of phagocytosis in
THP-1-derived macrophages pretreated with cytochalasin D for 1 h and then incubated for 3 h with FC.
Scale bars, 10 µm. Cells were stained for visualization of tubulin (anti-α-tubulin, red), beads, FC, Ec or
Pm (CFSE, green) and nuclei (DAPI, blue). (d) ELISA of IL-1β in the SN of THP-1-derived macrophages
pretreated with cytochalasin D for 1 h and then infected for 3 h with FC, Ec or Pm. *, p < 0.05; and **, p <
0.01. Arrow, phagocytosed E. faecalis. Closed arrowhead, phagocytosed FC, Ec or Pm. Open arrowhead,
unphagocytosed FC, Ec or Pm. These data are representative of three independent experiments.
Nutrients 2019, 11, 516 9 of 16
3.5. E. faecalis Pretreatment Protects Mice from DSS-Induced Acute Colitis
Mounting evidence supports the idea that NLRP3 plays a pro-inflammatory role in colitis
pathology [36–39]. In addition, it has been reported that blockage of IL-1β [27,40] or IL-18 [41]
reduces colitis. As the NLRP3 inflammasome appears to enhance the development of colitis, it has
been recommended as potential therapeutic target for the prevention of colitis and colitis-associated
CRC [42]. Therefore, we assessed whether E. faecalis pretreatment can protect mice from acute colitis
by reducing NLRP3 inflammasome activation, as assessed by monitoring weight loss and diarrhea
in the DSS-treated mouse model (Figure 4a). Indeed, we found that E. faecalis significantly reduced
DSS-induced weight loss compared to PBS control in wild type mice, but not in NLRP3-deficient mice
(Figure 4b). Similarly, E. faecalis-treated mice had reduced diarrhea scores compared with PBS-treated
control in wild type mice, but not in NLRP3-deficient mice (Figure 4c). Furthermore, the disease status
was assessed by the colon length, which is used as an indicator of disease severity [30]. E. faecalis-treated
mice had longer colons compared with PBS-treated control wild-type mice (8.5 cm vs. 7.6 cm), but
no differences were observed in NLRP3-deficient mice (7.0 cm vs. 7.1 cm) (Figure 4d). Next, we
examinutesed whether E. faecalis pretreatment affects inflammasome activation in vivo. As shown in
Figure 4e, the levels of cleaved (activated) caspase-1 and mature IL-1β were reduced by E. faecalis in
the colon tissues of mice with DSS-induced colitis compared to PBS control in wild type mice, but not
in NLRP3-deficient mice. These results demonstrate that E. faecalis pretreatment can protect mice from
DSS-induced acute colitis through an NLRP3-dependent manner.
3.6. E. faecalis Pretreatment Pprotects Mice from Colitis-Associated CRC
Since intestinal inflammation is an important risk factor for CRC development [2], we evaluated
the ability of E. faecalis pretreatment to attenuate colitis-associated CRC. Mice were pretreated with
E. faecalis and then treated with AOM and DSS to trigger the development of colitis-associated CRC
(Figure 5a). E. faecalis pretreatment significantly ameliorated the weight loss of AOM/DSS-treated
mice compared to PBS control mice (Figure 5b). E. faecalis-treated mice also presented with
significantly lower diarrhea scores (Figure 5c) and had longer colons (8.0 cm vs. 7.3 cm) (Figure 5d,e)
compared to PBS-treated control mice. Importantly, E. faecalis pretreatment inhibited the number
of AOM/DSS-induced colon tumors per mouse (Figure 5e). We also evaluated the potential use of
E. faecalis to treat the pre-existing CRC. Beginning at the end of the third DSS treatment, mice were
inoculated with E. faecalis every day for 34 days (Figure S3a). We did not observe any difference in %
weight change (Figure S3b) or diarrhea score (Figure S3c) between E. faecalis-treated and PBS control
mice. After daily inoculation with E. faecalis for 34 days, we also did not observe any difference in the
colon length (Figure S3d,e) or the number of colon tumors per mouse (Figure S3e). Taken together, our
results indicate that E. faecalis may exert protective effects against CRC but does not appear to act on
pre-existing CRC.
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Figure 5. E. faecalis pretreatment protects mice from colitis-associated CRC. (a) Schematic presentation
of the mouse model of colitis-associated CRC. Mice were orally inoculated with E. faecalis every day
during the course of experiment, starting two weeks before the adminutesistration of DSS. Mice were
injected intraperitoneally with AOM prior to beginning the first of three cycles of DSS in the drinking
water. One cycle was defined as 6 days of DSS followed by 14 days of water. 60 days after the start
of DSS treatment, all mice were sacrificed; n = 14 mice for the PBS control and E. faecalis-treated
groups. (b,c) Percent weight change (b) and diarrhea scores (c) were monitored daily in all mice.
(d) Representative images of colons. (e) Colon length and tumor number. Scale bars, 1 cm. *, p < 0.05;
and **, p < 0.01.
4. Discussion
Proper activation of the NLRP3 inflammasome is critical for immune defense, but improper
activation causes inflammatory disease. Previous studies showed that the NLRP3 inflammasome
contributes to the severity of DSS-induced acute colitis [36,37] and inherited spontaneous colitis [38,39].
Here, we introduce a useful and safe way to ameliorate acute colitis and attenuate colitis-associated
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CRC by oral treatment of heat-killed probiotic E. faecalis. Mechanistically, we show that pretreatment
of E. faecalis significantly attenuates the fecal content- and intestinal commensal microbe-induced
activation of the NLRP3 inflammasome in macrophages. Our results also reveal that E. faecalis interferes
with phagocytosis, which is required for full activation of the NLRP3 inflammasome. Together, these
findings provide functional and mechanistic evidence to support the use of E. faecalis for the attenuation
of colitis and colitis-associated CRC.
Bacterial environmental stimuli, conditioned by the inflammatory state of the intestine, are
thought to be the primary trigger that causes a commensal microbe to transition into a pathogen [43].
Recently, Seo et al. provided evidence that certain members of the microbiota, especially P. mirabilis, can
respond to the induction of DSS-induced colitis by inducing robust NLRP3 inflammasome-mediated
IL-1β production in recruited inflammatory macrophages, when then promotes IL-1β-dependent
inflammation and damage in the intestine [27]. Thus, appropriately limiting the inflammation induced
by harmless commensal microbes could benefit people suffering from the intestinal inflammation,
especially non-infectious inflammation, such as Crohn’s disease and chemotherapy-related diarrhea.
Here, we show that E. faecalis pretreatment attenuates the NLRP3 inflammasome activation and
IL-1β secondsretion in macrophages induced by fecal content or harmless commensal microbes,
including P. mirabilis (Figure 2), and that this occurs through a decrease in phagocytosis (Figure 3).
Importantly, E. faecalis pretreatment appeared to protect mice from DSS-induced acute colitis
(Figure 4) and the development of colitis-associated CRC (Figure 5). This suggests that, consistent
with the pro-inflammatory role of NLRP3 and IL-1β in intestinal inflammation, the E. faecalis
pretreatment-induced attenuation of NLRP3 inflammasome activity in macrophages can ameliorate
DSS-induced colitis. Our study supports the potential use of heat-killed E. faecalis to protect against
intestinal inflammation initiated by non-infectious agents. Similar to our findings, the probiotic
E. coli Nissle 1917 is markedly weaker than commensal E. coli K12 in its ability to activate the
inflammasome [44] and also has the ability to ameliorate ulcerative colitis in humans [45] and mice [46].
However, the potential of E. coli Nissle 1917 to prevent colitis-associated colorectal cancer remains
to be examinutesed. Beyond its effect on intestinal inflammation, the NLRP3 inflammasome is also
involved in Helicobacter pylori infection-induced chronic gastric inflammation [47], which is the main
cause of peptic ulcer disease and gastric cancer [48]. The degree of H. pylori infection-induced gastric
inflammation was lower in NLRP3-deficient mice than wild type mice [47]. Therefore, it was proposed
that the use of heat-killed E. faecalis may protect against peptic ulcer disease and gastric cancer in
people infected with H. pylori.
In addition to being expressed in macrophages, NLRP3 inflammasome components are also
expressed in intestinal epithelial cells, where they protect the mucosa by IL-18-dependently increasing
the production of mucus by goblet cells [49]. Although P. mirabilis exists in the intestinal lumen and
has contact with intestinal epithelial cells at the surface layer of the intestine, this commensal microbe
usually does not provoke an inflammatory response, and keeps peace with the healthy host. Here,
we observed that phagocytosis of this microbe is required for the ability of P. mirabilis to induce IL-1β
secondsretion in macrophages (Figure 3). This suggests that P. mirabilis should efficiently activate the
NLRP3 inflammasome in phagocytes, but not in non-phagocytic cells, such as intestinal epithelial cells.
Thus, although P. mirabilis exists in the intestinal lumen, it should be restricted to the extracellular
space and not enter the epithelial cells to directly activate the NLRP3 inflammasome under healthy
conditions. When there is epithelial damage, such as following DSS treatment, P. mirabilis might
cross the damaged epithelial layer from the intestinal lumen to laminutesa propria and reach the
recruited inflammatory macrophages [43]. After undergoing phagocytosis, the engulfed P. mirabilis
will strongly activate the NLRP3 inflammasome in inflammatory macrophages, leading to expansion
of the intestinal inflammation.
Considerable evidence supports the idea that NLRP3 inflammasome plays a pro-inflammatory
role in colitis pathology [36–39], and blockage of IL-1β [27,40] or IL-18 [41] has been reported to reduce
colitis. The NLRP3 inflammasome therefore appears to negatively affect the development of colitis.
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Indeed, it has been recommended as a potential therapeutic target for the prevention of colitis and
colitis-associated CRC [42]. The efficacy of NLRP3 inhibitors has been examinutesed in experimental
models of ulcerative colitis. For example, the diarylsulfonylurea-containing compound, MCC950,
was found to inhibit the activation of the NLRP3 inflammasome, but not activation of the AIM2,
NLRC4, or NLRP1 inflammasomes [50]. MCC950 can inhibit NLRP3 inflammasome activation and
IL-1β secondsretion in response to Escherichia coli stimulation in macrophages [51]. In a spontaneous
chronic colitis mouse model (Winnie mice), MCC950 reportedly attenuated colonic inflammation, as
assessed by significant improvements in body weight and colon length, accompanied by reduced IL-1β
secondsretion [39]. The benzo[d]imidazole derivative, Fc11a-2, was shown to inhibit the activation of
the NLRP3 inflammasome and prevent the development of DSS-induced acute colitis [37]. However,
these chemical inhibitors of the NLRP3 inflammasome may act directly on the NLRP3 molecule, and
thus could inhibit NLRP3 inflammasome activity in both phagocytic and non-phagocytic cells. Here,
we show that the probiotic E. faecalis interferes with phagocytosis to attenuate NLRP3 inflammasome
activation (Figure 3), and does not act directly on the NLRP3 molecule (Figure S2). We therefore
expect that E. faecalis does not affect the activation of the NLRP3 inflammasome in intestinal epithelial
cells. Accordingly, pretreatment with E. faecalis should restrain the NLRP3 inflammasome activity in
macrophages, which can worsen tissue damage in the inflamed intestine [27], without affecting NLRP3
activity in intestinal epithelial cells, which can aid in the recovery from intestinal tissue damage [49].
Of note, E. faecalis is present in the intestine and has been widely used as a probiotic microorganism in
probiotic foods, whereas the precise mechanisms through which the chemical inhibitors, MCC950 or
Fc11a-2, inhibit the NLRP3 inflammasome have not yet been clearly defined. Compared to MCC950
and Fc11a-2, the probiotic E. faecalis is expected to be safer. Thus, our present data collectively show a
useful and safe way in which E. faecalis can be used to ameliorate colitis and colitis-associated CRC.
Commensal microbes are usually harmless, but they may help promote intestinal inflammation
when there is epithelial damage, such as in Crohn’s disease and chemotherapy-related diarrhea.
Here, we provide evidence that pretreatment with heat-killed E. faecalis can efficiently attenuate
NLRP3 inflammasome activation in macrophages, and that this occurs through negative effects on
phagocytosis. Furthermore, E. faecalis can ameliorate the severity of DSS-induced murine experimental
colitis and the development of colitis-associated CRC in mice. Together, our findings indicate that
application of the probiotic, E. faecalis, may be a useful and safe strategy for treating colitis, especially
that initiated by non-infectious agents.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/11/3/516/s1,
Figure S1: Bacterial phagocytosis is inhibited by E. faecalis pretreatment, Figure S2: E. faecalis enhances ATP-
and nigericin -induced IL-1β secondsretion through upregulation of pro-IL -1β expression, Figure S3: E. faecalis
treatment does not appear to affect pre-existing colitis-associated CRC.
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